Русский
A comparative, randomized, uncontrolled study of the effectiveness of two regimens for the treatment of clinical manifestations of laryngopharyngeal reflux without esophageal symptoms
DOI: https://dx.doi.org/10.18565/pharmateca.2022.10.68-72
I.B. Angotoeva, I.D. Loranskaya, S.Ya. Kosyakov
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Background. Drug treatment of clinical manifestations of laryngopharyngeal reflux (LPR) without esophageal symptoms is an actual unsolved problem. Questions about the choice of the optimal treatment regimen, the choice of drugs, the use of proton pump inhibitors, their dosage and timing of treatment remain.
Objective. Comparison of the results of treatment of LPR clinical manifestations without esophageal symptoms with two antireflux therapy regimens.
Methods. TTwo study groups were randomly selected from patients with LPR symptoms without esophageal symptoms. The first group received monotherapy with omeprazole 20 mg 30 minutes before meals in the morning, Patients of the 2nd group received omeprazole 20 mg 30 minutes before meals in the morning, Gaviscon suspension 10 ml after meals and 1 time at night, nasal douche 2 times a day with saline NaCl solution 0.9%.
Results. The quantitative assessment of symptoms according to the RSI questionnaire when prescribing the 2nd treatment regimen as early as 2 weeks after the start of treatment was statistically significantly lower than when prescribing the 1st treatment regimen. After 6 weeks, the quantitative assessment of symptoms according to the RSI questionnaire for both treatment regimens did not differ statisti- cally significantly, but was statistically significantly less than at study entry. Changes during an objective examination of the ENT organs occured no earlier than the 6th week of antireflux therapy with both treatment regimens.
Conclusion. Symptoms of LPR decreased statistically significantly faster with the use of the 2nd treatment regimen (omeprazole 20 mg in the morning 30 minutes before meals, gaviscon suspension 10 ml 3 times a day after meals and 1 time at night, nasal douche 2 times a day). A statistically significant improvement in the results of an objective examination of the ENT organs occurred by the 6th week when both treatment regimens were prescribed. Therefore, the minimum duration of antireflux therapy is 6 weeks.
Objective. Comparison of the results of treatment of LPR clinical manifestations without esophageal symptoms with two antireflux therapy regimens.
Methods. TTwo study groups were randomly selected from patients with LPR symptoms without esophageal symptoms. The first group received monotherapy with omeprazole 20 mg 30 minutes before meals in the morning, Patients of the 2nd group received omeprazole 20 mg 30 minutes before meals in the morning, Gaviscon suspension 10 ml after meals and 1 time at night, nasal douche 2 times a day with saline NaCl solution 0.9%.
Results. The quantitative assessment of symptoms according to the RSI questionnaire when prescribing the 2nd treatment regimen as early as 2 weeks after the start of treatment was statistically significantly lower than when prescribing the 1st treatment regimen. After 6 weeks, the quantitative assessment of symptoms according to the RSI questionnaire for both treatment regimens did not differ statisti- cally significantly, but was statistically significantly less than at study entry. Changes during an objective examination of the ENT organs occured no earlier than the 6th week of antireflux therapy with both treatment regimens.
Conclusion. Symptoms of LPR decreased statistically significantly faster with the use of the 2nd treatment regimen (omeprazole 20 mg in the morning 30 minutes before meals, gaviscon suspension 10 ml 3 times a day after meals and 1 time at night, nasal douche 2 times a day). A statistically significant improvement in the results of an objective examination of the ENT organs occurred by the 6th week when both treatment regimens were prescribed. Therefore, the minimum duration of antireflux therapy is 6 weeks.
About the Autors
Corresponding author: Irina B. Angotoeva, Cand. Sci. (Med.), Associate Professor, Department of Otorhinolaryngology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; angotoeva@mail.ru
Similar Articles
